3D Systems Corporation — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This filing reports annual results; the supplied text does not provide a clear standalone Q4 income statement or Q4-specific financial metrics. 3D Systems sells 3D printers, materials, software and related services, organized into Healthcare and Industrial segments.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $615.6 million | $557.2 million |
| Gross profit / margin | $263.8 million / 42.8% | $223.4 million / 40.1% |
| Operating loss | $(33.1) million | $(119.0) million |
| Net income (loss) | $322.1 million | $(149.6) million |
| Operating cash flow | $48.1 million | $(20.1) million |
| Cash and cash equivalents at year-end | $789.7 million | $75.0 million |
- Revenue grew 10.5%. Products revenue rose to $428.7 million, while services revenue declined to $186.9 million, largely reflecting divestitures.
- Healthcare revenue increased 24.2% to $306.2 million; Industrial revenue decreased 0.4% to $309.5 million. Segment operating profit was $69.4 million for Healthcare and $48.6 million for Industrial, before $151.0 million of net corporate expense.
- Product gross margin improved to 42.8% from 33.8%; services gross margin fell to 42.9% from 49.5%. Consolidated margin improvement reflected higher production and the absence of prior-year inventory and cost-optimization charges, partly offset by divestitures.
- FY2021 net income included a $350.9 million net gain on business divestitures in “interest and other income.” The company remained loss-making at the operating level.
- Cash from investing activities was $260.6 million, including $421.5 million net proceeds from asset and business sales, partly offset by $139.7 million for acquisitions and $18.8 million of capital expenditures. Financing activities provided $405.8 million, principally from convertible notes.
- Year-end debt included $460 million principal amount of 0% convertible notes due November 2026; the balance-sheet carrying amount, net of issuance costs, was $446.9 million. The prior term loan was repaid and the revolving credit facility terminated in 2021.
Material changes and transactions
- Divested Cimatron for approximately $64.2 million, Simbionix for $305.0 million and On Demand Manufacturing for $82.0 million. The sales generated reported gains, with Simbionix contributing the largest gain.
- Acquired Oqton for $188.2 million and Volumetric for $40.2 million, and also acquired Allevi and Additive Works. Management expected the near-term operating and cash-flow impact of Oqton and Volumetric to be dilutive.
- Volumetric consideration may include up to $355 million of additional payments tied to long-dated non-financial milestones and continued employment; payments are expected to be approximately half cash and half stock.
- Completed the 2020 restructuring program in Q2 2021. Restructuring charges were $1.1 million in 2021 versus $20.1 million in 2020.
- One customer represented approximately 22% of FY2021 revenue, up from 13% in FY2020. Revenue concentration also creates significant receivables and credit exposure.
Outlook, risks and unusual items
- Management expects positive operating cash flow in 2022 and believes available cash, operating cash flow and other funding sources will meet foreseeable requirements. No numeric revenue or earnings guidance is provided in the supplied filing text.
- Key risks include uncertain COVID-19 effects, supply-chain and logistics disruptions, uneven sales timing, product-mix-driven margin volatility, foreign-exchange exposure, and dependence on limited suppliers and a major customer.
- Export-control and sanctions investigations remain ongoing, including federal grand-jury subpoenas and voluntary disclosures. The Air Force ended its compliance monitorship in August 2021 and the company is again eligible for U.S. government contracts without restrictions. The company says it cannot estimate any eventual penalties or liabilities and expects further legal costs.
- A securities class action and related derivative lawsuits are pending; the company says it believes the claims are without merit and intends to defend them. The filing does not provide a clear quantified loss estimate.
- Management identified three material weaknesses in internal control over financial reporting: non-standard contract review, review of financial-close analyses, and income-tax provision calculations. Management concluded disclosure controls were ineffective, and the auditor issued an adverse opinion on internal control, while issuing an unqualified opinion on the financial statements. Remediation was ongoing, with management targeting 2022 but giving no assurance of timing or outcome.
- Other notable items include $55.2 million of stock-based compensation, a $91.2 million valuation allowance against deferred tax assets, and substantial foreign-currency translation losses in other comprehensive income.
Investor verification priorities
- Separate recurring operating performance from the $350.9 million divestiture gain; review the operating loss and segment results after corporate costs.
- Assess whether Healthcare growth and recurring revenue can offset services declines and the continuing effects of divestitures.
- Evaluate liquidity against the $460 million 2026 convertible-note principal, lease obligations and possible Volumetric milestone payments.
- Track the 22% customer concentration, its receivables exposure and any change in order levels or credit quality.
- Monitor export-control investigations, shareholder litigation and any resulting penalties, restrictions or additional legal expenses.
- Verify progress in remediating all three material weaknesses and the effect of control remediation on future reporting reliability.